Citations

Showing 10 of 108135 citations.

Krüppel‐like factor 10 regulates the contractile properties of skeletal muscle fibers in mice
Kammoun, Malek , Pouletaut, Philippe , Morandat, Sandrine , Subramaniam, Malayannan , Hawse, John R. , Bensamoun, Sabine F. , Bensamoun, Sabine F

Mayo Clinic

Muscle & Nerve | September 6, 2021 | Volume: 64 | Issue: 6 | Pages: 765-769

10.1002/mus.27412 | PMID 34486132 Get It

AbstractIntroduction/AimsKlf10 is a member of the Krüppel‐like family of transcription factors, which is implicated in mediating muscle structure (fiber size, organization of the sarcomere), muscle metabolic activity (respiratory chain), and passive force. The aim of this study was to further characterize the roles of Klf10 in the contractile properties of skeletal muscle fibers.MethodsFifty‐two single fibers were extracted from female wild‐type (WT) and Klf10 knockout (KO) oxidative (soleus) and glycolytic (extensor digitorum longus [EDL]) skinned muscles. Each fiber was immersed successively in relaxing (R), washing (W), and activating (A) solutions. Calcium was included in the activating solution to induce a maximum contraction of the fiber. The maximum force (Fmax) was measured and normalized to the cross‐sectional area to obtain the maximum stress (Stressmax). After a steady state in contraction was reached, a quick stretch‐release was performed; the force at the maximum stretch (Fstretch) was measured and the stiffness was assessed.ResultsDeletion of the Klf10 gene induced changes in the contractile parameters (Fmax, Stressmax, Stiffness), which were lower and higher for soleus and EDL fibers compared with littermates, respectively. These measurements also revealed changes in the proportion and resistance of attached cross‐bridges.DiscussionKlf10 plays a major role in the homeostasis of the contractile behavior of skeletal muscle fibers in a muscle fiber type–specific manner. These findings further implicate important roles for Klf10 in skeletal muscle function and shed new light on understanding the molecular processes regulating the contractility of skeletal muscle fibers.
Skimmed breast milk for treatment of hypertriglyceridemia in an infant with congenital nephrotic syndrome
Dahl, Amanda , Armellino, A., Tran, Cheryl L. , Tebben, Peter J. , Dahl, Amanda R , Armellino, Andrea L, Tebben, Peter

Mayo Clinic

Nutrition in Clinical Practice | September 6, 2021 | Volume: 37 | Issue: 2 | Pages: 383-387

10.1002/ncp.10759 | PMID 34486165 Get It

AbstractCongenital nephrotic syndrome (CNS) is a complex condition that requires multidisciplinary care. Hyperlipidemia is a characteristic feature with elevation of serum cholesterol and triglycerides. Little evidence is available to guide treatment of dyslipidemia in infants with CNS. We describe successful treatment of severe hypertriglyceridemia through dietary changes in a boy with CNS. A 9‐day‐old boy presented to the emergency department with lower extremity edema caused by deep venous thrombosis. Laboratory evaluation identified hypoalbuminemia, nephrotic‐range proteinuria, and a pathogenic variant of the NPHS1 gene. The initial triglyceride concentration of 369 mg/dl increased to 3096 mg/dl by 5 weeks of age, when his diet consisted of breast milk. Refrigerated breast milk was skimmed by removing the top layer after allowing it to separate for 24 h. This process was repeated prior to use. Skimmed breast milk was supplemented with medium‐chain triglyceride oil and an infant protein powder. After 2 days, the triglyceride concentration declined to 481 mg/dl and, by day 10, to 148 mg/dl. When breast milk supply decreased, a 1:1 ratio of skimmed maternal breast milk to an elemental, very low‐fat formula was utilized. The triglyceride concentration remained below 400 mg/dl for the first year of life, except when skimmed breast milk was not available during hospitalization. Severe hypertriglyceridemia caused by CNS can present in the neonatal period and be difficult to manage. In our patient, skimmed maternal breast milk was successful in reducing the triglyceride concentration and should be considered a therapeutic option for children with hyperlipidemia caused by CNS.
Pre‐clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease
Mise, Annarita Di , Ye, Hong , Pellegrini, Lorenzo, Torres, Vicente E. , Di Mise, Annarita , Torres, Vicente E , Wang, Xiaofang , Valenti, Giovanna

Mayo Clinic

The FASEB Journal | September 6, 2021 | Volume: 35 | Issue: 10 | Pages: No page available

10.1096/fj.202100774r | PMID 34486176 Get It

Abstract Autosomal dominant polycystic kidney disease (ADPKD), caused by mutations of PKD1 or PKD2 genes, is characterized by development and growth of cysts causing progressive kidney enlargement. Reduced resting cytosolic calcium and increased cAMP levels associated with the tonic action of vasopressin are two central biochemical defects in ADPKD. Here we show that co‐targeting two GPCRs, the vasopressin V2 receptor (V2R) and the calcium sensing receptor, using the novel V2R antagonist lixivaptan in combination with the calcimimetic R‐568, reduced cyst progression in two animal models of human PKD. Lixivaptan is expected to have a safer liver profile compared to tolvaptan, the only drug approved to delay PKD progression, based on computational model results and initial clinical evidence. PCK rat and Pkd1 RC/RC mouse littermates were fed without or with lixivaptan (0.5%) and R‐568 (0.025% for rats and 0.04% for mice), alone or in combination, for 7 (rats) or 13 (mice) weeks. In PCK rats, the combined treatment strongly decreased kidney weight, cyst and fibrosis volumes by 20%, 49%, and 73%, respectively, compared to untreated animals. In Pkd1 RC/RC mice, the same parameters were reduced by 20%, 56%, and 69%, respectively. In both cases the combined treatment appeared nominally more effective than the individual drugs used alone. These data point to an intriguing new application for two existing drugs in PKD treatment. The potential for synergy between these two compounds suggested in these animal studies, if confirmed in appropriate clinical investigations, would represent a welcome advancement in the treatment of ADPKD.
Multiparametric magnetic resonance imaging/magnetic resonance elastography assesses progression and regression of steatosis, inflammation, and fibrosis in alcohol‐associated liver disease
Chen, Jingbiao , Martín‐Mateos, Rosa , Li, Jiahui , Yin, Ziying , Chen, Jie , Lü, Xin , Glaser, Kevin J. , Mounajjed, Taofic, Yashiro, Hiroaki , Siegelman, Jenifer , Winkelmann, Christopher T. , Wang, Jin , Shah, Vijay H. , Yin, Meng , Yin, Meng , Yin, Ziying , Li, Jiahui , Ehman, Richard L.

Mayo Clinic

Alcoholism: Clinical and Experimental Research | September 6, 2021 | Volume: 45 | Issue: 10 | Pages: 2103-2117

10.1111/acer.14699 | PMID 34486129 Get It

Abstract Background Magnetic resonance imaging (MRI) and MRI‐based elastography (MRE) are the most promising noninvasive techniques in assessing liver diseases. The purpose of this study was to evaluate an advanced multiparametric imaging method for staging disease and assessing treatment response in realistic preclinical alcohol‐associated liver disease (ALD). Methods We utilized four different preclinical mouse models in our study: Model 1—mice were fed a fast‐food diet and fructose water for 48 weeks to induce nonalcoholic fatty liver disease; Model 2—mice were fed chronic‐binge ethanol (EtOH) for 10 days or 8 weeks to induce liver steatosis/inflammation. Two groups of mice were treated with interleukin‐22 at different time points to induce disease regression; Model 3—mice were administered CCl 4 for 2 to 4 weeks to establish liver fibrosis followed by 2 or 4 weeks of recovery; and Model 4—mice were administered EtOH plus CCl 4 for 12 weeks. Mouse liver imaging biomarkers including proton density fat fraction (PDFF), liver stiffness (LS), loss modulus (LM), and damping ratio (DR) were assessed. Liver and serum samples were obtained for histologic and biochemical analyses. Ordinal logistic regression and generalized linear regression analyses were used to model the severity of steatosis, inflammation, and fibrosis, and to assess the regression of these conditions. Results Multiparametric models with combinations of biomarkers (LS, LM, DR, and PDFF) used noninvasively to predict the histologic severity and regression of steatosis, inflammation, and fibrosis were highly accurate (area under the curve > 0.84 for all). A three‐parameter model that incorporates LS, DR, and ALT predicted histologic fibrosis progression ( r = 0.84, p < 0.0001) and regression ( r = 0.79, p < 0.0001) as measured by collagen content in livers. Conclusion This preclinical study provides evidence that multiparametric MRI/MRE can be used noninvasively to assess disease severity and monitor treatment response in ALD.
Epigenomic features related to microglia are associated with attenuated effect of APOE ε4 on Alzheimer's disease risk in humans
Yu, Lei , Olah, Marta , Smith, Rebecca G. , Oatman, Stephanie R., Allen, Mariet , Pishva, Ehsan , Zhang, Bin , Ertekin‐Taner, Nilüfer , Bennett, David A. , Klein, Hans‐Ulrich , Jager, Philip L. De , Bennett, David A. , Ma, Yiyi , Menon, Vilas , Lunnon, Katie

Mayo Clinic

Alzheimer's & Dementia | September 5, 2021 | Volume: 18 | Issue: 4 | Pages: 688-699

10.1002/alz.12425 | PMID 34482628 Get It

Abstract Not all apolipoprotein E ( APOE ) ε4 carriers who survive to advanced age develop Alzheimer's disease (AD); factors attenuating the risk of ε4 on AD may exist. Guided by the top ε4‐attenuating signals from methylome‐wide association analyses (N = 572, ε4+ and ε4–) of neurofibrillary tangles and neuritic plaques, we conducted a meta‐analysis for pathological AD within the ε4+ subgroups (N = 235) across four independent collections of brains. Cortical RNA‐seq and microglial morphology measurements were used in functional analyses. Three out of the four significant CpG dinucleotides were captured by one principal component (PC1), which interacts with ε4 on AD, and is associated with expression of innate immune genes and activated microglia. In ε4 carriers, reduction in each unit of PC1 attenuated the odds of AD by 58% (odds ratio = 2.39, 95% confidence interval = [1.64,3.46], P = 7.08 × 10 –6 ). An epigenomic factor associated with a reduced proportion of activated microglia (epigenomic factor of activated microglia, EFAM) appears to attenuate the risk of ε4 on AD.
Medical and nursing home costs: From cognitively unimpaired through dementia
Long, Kirsten Hall , Petersen, Ronald C. , Emerson, Jane A., Ransom, Jeanine E. , Leibson, Cynthia L., Emerson, Jane, Ransom, Jeanine, Leibson, Cynthia, Smith, Carin Y. , Mielke, Michelle M. , Hass, Steven

Mayo Clinic

Alzheimer's & Dementia | September 5, 2021 | Volume: 18 | Issue: 3 | Pages: 393-407

10.1002/alz.12400 | PMID 34482623 Get It

AbstractIntroductionEfforts to model the cost‐effectiveness of managing/modifying cognitive impairment lack reliable, objective, baseline medical, and nursing‐home (NH) costs.MethodsA stratified‐random sample of Olmsted County, MN, residents ages 70–89 years (N = 3545), well‐characterized as cognitively unimpaired, mild cognitive impairment (MCI), or dementia, were followed forward ≤1 year in provider‐linked billing data and the Centers for Medicare & Medicaid Services NH assessments. Direct medical/nursing home/medical + NH costs were estimated. Costs were stratified by vital status and NH‐use intensity (NH days/follow‐up days [0%, 1% to 24%, 25% to 99%, and 100%]). Between‐category mean‐annual cost differences were adjusted for patient characteristics and follow‐up days.ResultsCosts/follow‐up day distributions differed significantly across cognitive categories. Mean costs/follow‐up days were 2.5 to 18 times higher for decedents versus survivors. Among all persons with MCI, <9% with any NH use accounted for 18% of all total annual medical + NH costs. Adjusted‐between‐category comparisons revealed significantly higher medical and medical + NH costs for MCI versus cognitively unimpaired.DiscussionCost‐effectiveness for managing/modifying both MCI and dementia should consider end‐of‐life costs and NH‐use intensity. Results can help inform cost‐effectiveness models, predict future‐care needs, and aid decision‐making by individuals/providers/payers/policymakers.
Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside
Jayaraman, Swaathi , Reid, Joel M. , Hawse, John R. , Goetz, Matthew P. , Goetz, Matthew P , Reid, Joel M

Mayo Clinic

Endocrinology | September 4, 2021 | Volume: 162 | Issue: 12 | Pages: No page available

10.1210/endocr/bqab191 | PMID 34480554 Get It

Abstract The selective estrogen receptor (ER) modulator, tamoxifen, is the only endocrine agent with approvals for both the prevention and treatment of premenopausal and postmenopausal estrogen-receptor positive breast cancer as well as for the treatment of male breast cancer. Endoxifen, a secondary metabolite resulting from CYP2D6-dependent biotransformation of the primary tamoxifen metabolite, N-desmethyltamoxifen (NDT), is a more potent antiestrogen than either NDT or the parent drug, tamoxifen. However, endoxifen’s antitumor effects may be related to additional molecular mechanisms of action, apart from its effects on ER. In phase 1/2 clinical studies, the efficacy of Z-endoxifen, the active isomer of endoxifen, was evaluated in patients with endocrine-refractory metastatic breast cancer as well as in patients with gynecologic, desmoid, and hormone-receptor positive solid tumors, and demonstrated substantial oral bioavailability and promising antitumor activity. Apart from its potent anticancer effects, Z-endoxifen appears to result in similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with tamoxifen. In this review, we summarize the preclinical and clinical studies evaluating endoxifen in the context of breast and other solid tumors, the potential benefits of endoxifen in bone, as well as its emerging role as an antimanic agent in bipolar disorder. In total, the summarized body of literature provides compelling arguments for the ongoing development of Z-endoxifen as a novel drug for multiple indications.
Glioblastoma as an age-related neurological disorder in adults
Kim, Miri , Mozny, Andreas , Kocherginsky, Masha , O’Shea, Kaitlyn , Zhai, Lijie , Bollu, Lakshmi Reddy , Rabin, Erik E. , Dixit, Karan , Kumthekar, Priya , Platanias, Leonidas C. , Hou, Lifang , Wu, Jennifer D. , Hrachova, Maya , Merrill, Sarah , Mrugała, Maciej M. , Prabhu, Vikram C. , James, C. David , Ostrom, Quinn T. , Johnson, Margaret , Reardon, David A. , Lukas, Rimas V. , Kumthekar, Priya , Merrill, Sarah A , Wainwright, Derek A , Kim, Miri , Wu, Jennifer , Hou, Lifang , Ladomersky, Erik , Reinstein, Zachary Z. , Bell, April , Lauing, Kristen L. , Zheng, Yinan , Zhang, Bin , Horbinski, Craig , Yamini, Bakhtiar , Ostrom, Quinn T

Mayo Clinic

Neuro-Oncology Advances | September 4, 2021 | Volume: 3 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdab125 | PMID 34647022 Get It

Abstract Background Advanced age is a major risk factor for the development of many diseases including those affecting the central nervous system. Wild-type isocitrate dehydrogenase glioblastoma (IDHwt GBM) is the most common primary malignant brain cancer and accounts for ≥90% of all adult GBM diagnoses. Patients with IDHwt GBM have a median age of diagnosis at 68–70 years of age, and increasing age is associated with an increasingly worse prognosis for patients with this type of GBM. Methods The Surveillance, Epidemiology, and End Results, The Cancer Genome Atlas, and the Chinese Glioma Genome Atlas databases were analyzed for mortality indices. Meta-analysis of 80 clinical trials was evaluated for log hazard ratio for aging to tumor survivorship. Results Despite significant advances in the understanding of intratumoral genetic alterations, molecular characteristics of tumor microenvironments, and relationships between tumor molecular characteristics and the use of targeted therapeutics, life expectancy for older adults with GBM has yet to improve. Conclusions Based upon the results of our analysis, we propose that age-dependent factors that are yet to be fully elucidated, contribute to IDHwt GBM patient outcomes.
Crimean‐Congo haemorrhagic fever‐induced liver injury: A systematic review and meta‐analysis
Manju, Ade Harrison, Wen, Qingqing, Sondhi, Manush , Pydi, Reshma , Haddad, Iskander, Hasan, Jamal, Ali, Muhammad , Tousif, Sohaib , Muhammed, Abdul‐Azeez, Ahmed, Noman Khurshid, Patel, Deep, Singh, Romil , Rathore, Sawai Singh , Hasan, Jamal

Mayo Clinic

International Journal of Clinical Practice | September 4, 2021 | Volume: 75 | Issue: 11 | Pages: No page available

10.1111/ijcp.14775 | PMID 34480502 Get It

Adenomatoid tumours of the gastrointestinal tract – a case‐series and review of the literature
Hissong, Erika , Graham, Rondell P. , Wen, Kwun Wah , Alpert, Lindsay , Shi, Jiaqi , Lamps, Laura W. , Graham, Rondell P

Mayo Clinic

Histopathology | September 4, 2021 | Volume: 80 | Issue: 2 | Pages: 348-359

10.1111/his.14553 | PMID 34480486 Get It

AimsAdenomatoid tumours are mesothelial‐derived benign neoplasms with a predilection for the genital tract. Extragenital sites are rare and can cause significant diagnostic challenges. Herein, we describe the clinicopathological features of a cohort of adenomatoid tumours involving the gastrointestinal tract and liver in order to more clearly characterise their histological findings and aid in diagnosis.Methods and resultsThe pathology databases at four institutions were searched for adenomatoid tumours involving the gastrointestinal tract or liver, yielding eight cases. Available clinicoradiological and follow‐up data were collected from the medical records. Six tumours were incidentally discovered during imaging studies or at the time of surgical exploration for unrelated conditions; presenting symptoms were unknown in two patients. Histologically, the tumours were well‐circumscribed, although focal ill‐defined borders were present in four cases. No infiltration of adjacent structures was identified. Architectural heterogeneity was noted in five (63%) tumours; an adenoid pattern often predominated. The neoplastic cells were flattened to cuboidal with eosinophilic cytoplasm. Cytoplasmic vacuoles mimicking signet ring‐like cells were present in five (63%) cases. Three (38%) cases showed involvement of the mesothelium with reactive mesothelial hyperplasia. Cytological atypia or increased mitotic activity was not identified. The surrounding stroma ranged from oedematous/myxoid to densely hyalinised. Immunohistochemistry confirmed mesothelial origin in all cases evaluated. No patients developed recurrence of disease.ConclusionsThe current study evaluates the clinicopathological findings in a collective series of gastrointestinal and hepatic adenomatoid tumours, correlating with those described in individually reported cases. We highlight common histological features and emphasise variable findings that could mimic a malignant neoplasm.